1. Home
  2. BOF vs ENTX Comparison

BOF vs ENTX Comparison

Compare BOF & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BranchOut Food Inc.

BOF

BranchOut Food Inc.

N/A

Current Price

$4.15

Market Cap

49.6M

ML Signal

N/A

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.99

Market Cap

58.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOF
ENTX
Founded
2017
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.6M
58.2M
IPO Year
2023
2015

Fundamental Metrics

Financial Performance
Metric
BOF
ENTX
Price
$4.15
$1.99
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.00
AVG Volume (30 Days)
82.4K
2.9M
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
31.33
N/A
EPS
N/A
0.07
Revenue
$3,184,018.00
$42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$25.57
Revenue Growth
258.20
N/A
52 Week Low
$1.93
$0.91
52 Week High
$5.25
$3.22

Technical Indicators

Market Signals
Indicator
BOF
ENTX
Relative Strength Index (RSI) 46.22 74.22
Support Level $2.92 $1.45
Resistance Level $4.06 $2.04
Average True Range (ATR) 0.34 0.17
MACD -0.09 0.02
Stochastic Oscillator 2.40 88.03

Price Performance

Historical Comparison
BOF
ENTX

About BOF BranchOut Food Inc.

Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: